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Abstract
Background: Cervical cancer (CC) is the fourth most common cancer in women worldwide with an estimated
528,000 new cases in 2012. The same year México had an incidence of 13,960 and a mortality of 4769 cases. There
are several diagnosis methods of CC; among the most frequents are the conventional Pap cytology (Pap),
colposcopy, and visual inspection with acetic acid (VIA), histopathological examination, tests of imaging and
detection of high-risk papilloma virus (HR-HPV) with molecular tests (PCR, hybridization, sequencing). Proteomics is
a tool for the detection of new biomarkers that can be associated with clinical stage, histological type, prognosis,
and/or response to treatment. In this study we performed a comparative analysis of CC cells with normal cervical
cells. The proteomic analysis was carried out with the fluorescent two-dimensional electrophoresis (2D-DIGE)
technique to subsequently identify differential protein profiles using Decyder Software, and the selected proteins
were identified by Mass Spectrometry (MALDI-TOF).
Results: The proteins that showed an increased expression in cervical cancer in comparison with normal cervix
cells were: Mimecan, Actin from aortic smooth muscle and Lumican. While Keratin, type II cytoskeletal 5,
Peroxiredoxin-1 and 14-3-3 protein sigma showed a decrease in their protein expression level in cervical cancer in
comparison with normal cervix cells.
Conclusions: Thus, this study was successful in identifying biomarker signatures for cervical cancer, and might
provide new insights into the mechanism of CC progression.
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Background
Cervical cancer is the fourth most common malignancy
and accounts for 10–15 % of cancer-related deaths in
women worldwide [1, 2]. Cervical cancer affects approxi-
mately six out of 100,000 women and accounts for approxi-
mately 275,000 deaths annually in developing countries,
which corresponds to 88 % of cases worldwide [2, 3].
Human papillomavirus (HPV) is the main etiological
agent of cervical cancer detected in 95 to 100 % of cases
[4–6]. Although more than 150 variants of this virus
exist, only certain genotypes, such as HPV 16, 18, 33, 45
and 58 are known as high-risk types (HR-HPV); low-risk
HPV types (LR-HPV), mainly HPV 6 and 11, seldom
cause genital tumors; however, they do cause condyl-
omata acuminata (anogenital warts) [7]. Persistent HPV
oncoprotein expression (E6/E7) in HPV infected epithe-
lial basal cells deregulates cell division [8]. Overexpres-
sion of these viral genes causes the deregulation of cell
proliferation, metabolism, apoptosis, differentiation and
genomic instability, all of which may lead to consecutive
stages of cervical cancer [9].
Current approaches for the prevention of cervical can-
cer relies mainly on the cytologic screening, known as
the Pap test, often combined with the detection of high-
risk human papillomaviruses (HR-HPVs) [10]. Patients
with abnormal Paps undergo colposcopy with directed
biopsies. If precursor lesions are identified, patients are
treated by cryotherapy or loop electrosurgical excision
procedure (LEEP). The treatment is effective in the pre-
vention of cervical cancer; however, it is expensive, cum-
bersome, and dependent on very good infrastructure
and well-trained personnel [11]. Nevertheless, the diag-
nosis may results in a poor outcome, which lies on the
lack of valuable objective indicators for determining cer-
vical chronic inflammation, reactive hyperplasia, and be-
nign or malignant lesions [12].
Compared with conventional 2-DE, two-dimensional dif-
ferential in-gel electrophoresis (2D-DIGE)-based quantitative
proteomics has several advantages, such as higher sensitiv-
ity, accuracy, and reproducibility, which facilitate spot-to-
spot comparisons, precisely because of pre-labeling of
protein samples with different fluorescent dyes (Cy3, and
Cy5) prior to separation by 2-DE [13]. As a result, samples
labeled with different dyes are separated in the same 2D
gel; moreover, the same internal standard is used in all gels
to avoid inter-gel variation [12, 14]. In the present study, a
differential proteomic technique was applied for the com-
parative analysis of cervical cancer samples infected with
HPV 16 and normal cervical tissue.
Results
To carry out a comparative analysis of cervical cancer/
HPV-16 and normal samples without HPV, a proteomic
analysis was done. Two groups of pooled samples were
used. The first one consisted of six samples from women
(average age of 50.7 years) diagnosed with HPV-16, by
the INNOLIPA assay, and with histopathological staging
of squamous cell carcinoma (SCC) of which four cases
were stage IIB, one stage IB1 and one case stage IB2.
The second group consisted of four pooled samples
from women (mean age of 49.8 years) with normal cy-
tology and colposcopy and negative for HPV infection.
In Fig. 1 is observed the proliferation index of the cer-
vical tissues by immunohistochemistry. Figure 2 shows
the protein profile of each pooled sample, used as a
reference pattern, allowing the visualization of more
than 2204 spots that were resolved for each 2D gel ana-
lyzed. The samples were pooled in two groups and ana-
lyzed by triplicated and whose profiles showed technical
reproducibility.
To compare samples, Decyder software (www.gelifes-
ciences.com) was used, which is a platform that allows
the qualitative and quantitative evaluation of spots pro-
files from fluorescent bidimensional electrophoresis gels
(DIGE) (Fig. 3).
Fig. 1 Expression of Ki-67. a Without SIL and HPV infection tissue showing nuclear immunostaining was exclusively confined to the parabasal
layers of normal epithelium (b) SCC and HPV-16 infection tissue showing strong immunostaining of Ki-67 in large pleomorphic nuclei of
malignant squamous cells form irregular nests invading the stroma. 40 X Immunohistochemistry
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The profile of proteins achieved under these condi-
tions was reproducible among pools, the comparison
showed different areas of differential expression (yellow
spots). An area with a differential expression pattern
among samples was located, from which 129 spots with
a diminishing expression and 150 with increased
expression +/− 5 times, 53 spots showed a greater differ-
ential expression and the identification of the ten spots
was achieved by Mass Spectrometry (MALDI-TOF).
Figure 4 shows that Mimecan, Actin aortic smooth
muscle and Lumican increased their expression in cer-
vical cancer, in comparison with normal cervical cells,
while Keratin, type II cytoskeletal 5, Peroxiredoxin-1 and
14-3-3 protein sigma showed a decrease in their protein
expression pattern in cervical cancer in comparison with
no SIL tissues.
Table 1 shows the identification of proteins and some
biochemical characteristics as name, identification code,
and chromosomal localization among others.
Analyzing the participation of the identified proteins
in different cellular pathways through Reactome Data-
base (www.reactome.org), the results suggest biosyn-
thesis, metabolism and degradation of keratan sulfate,
transcriptional regulation by TP53, metabolism of carbo-
hydrates, intrinsic pathway for apoptosis, detoxification
of reactive oxygen species, and cell cycle as the most
important.
Discussion
In 2012 the CC was the second cause of cancer death in
Mexican women [15], HPV-16 has been reported in
studies carried out by our group, as the more common
in populations of women of the southern region of
Mexico since 1997 [16, 17].
Multiple genes are involved in the occurrence and de-
velopment of cancers, and even tough genes carry the
genetic information, proteins are the final executors of
life events [1]. Due to this, the proteomic profiling offers
Fig. 2 Bidimensional electrophoresis of squamous cell carcinoma HPV-16 pool vs control cervical cells without HPV infection pool. Gel representative
of processing samples, normal cervical cells (left), cervical cancer (rigth). More than 2000 proteins were resolved
Fig. 3 Representative 2D-DIGE proteome map of control cervical
cells sample vs cervical cancer sample. (Control cervical cells without
HPV 16 infection, stained with Cy3 (green), and a cervical cancer
group stained with Cy5 (red), and overlapping of two groups stained
with Cy3 and Cy5 (yellow). The samples were processed through
PAGE at 10 %
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Fig. 4 Comparison of protein expression levels among normal cervical cells without HPV infection, and cervical cancer HPV16 infection groups.
Decyder software allowed the tridimensional comparisons between study groups
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an option for the selection of differential protein pat-
terns whose expression levels could be associated with
progression, prognosis and/or survival.
There have been several experimental approaches for
the analysis of differential protein expression in cervical
cancer, such as the analysis of tissues [12], cells [1], and
even plasma samples [12]. In this study, cells that come
from women with cervical cancer and infection with
HPV-16 were compared with normal cells of the cervix
recovered from individuals without HPV infection, diag-
nosed through INNOLIPA assay and in situ hybridization
with tyramide amplification.
Bidimensional electrophoresis is a very useful tool to
analyze broad and complex samples, through the wide
distribution of protein profiles based on their isoelectric
points and molecular weights. The additional use of
fluorescence during this technique allows for an increase
in sensitivity in 2D DIGE, and the use of special software
facilitates the differential analysis. Finally, the use of
MALDI-TOF MS, allowed the successful identification
of ten differentially expressed proteins among the two
different groups.
In the present study, the proteins identified were
mimecan (osteoglycine), aortic smooth muscle, Lumican,
Peroxiredoxin-1, 14-3-3 protein sigma, Alpha-enolase,
Keratin, type II cytoskeletal 5, as differential proteins
among cervical cancer and normal cervical cells, whose
expression patterns were either increased or diminished.
Mimecan (or Osteoglycin, OGN), is a secretory protein
that belongs to a family of small leucine rich proteogly-
can (SLRPs). It has been found in several cancer cell
lines, although its physiological function has not been
completely understood [18, 19], being abundant in bone
matrix, cartilage cells, and connective tissues; it is also
important for collagen fibrillogenesis, cellular growth,
differentiation and migration [20] and it has been in-
volved in the pathogenesis of different cancers such as
colorectal [21], laryngeal carcinoma [19] and cervical
cancer.
The actin cytoskeleton is substantially altered in can-
cer cells as a result of the changes in the abundance of
proteins, among other factors. As a result, cancer cells
acquire increased motility and distinctive mechanical
properties, which are important for processes such as in-
vasion and metastasis [22]. ACTA2 is a α-smooth
muscle actin whose expression is transformation sensi-
tive to growth signals in normal cells [23].
In cases of basal cell carcinoma skin cancer, it has
been found with a high expression too, both in the
tumor and in the adjacent stroma and it is used as a
marker of aggressiveness in pancreatic cancer, because it
is presenting more aggressive histological variants [24],
suggesting that the increased expression may contribute
to the local invasion. It’s role in the biology of the tumor
is not completely known, however, it has been hypothe-
sized that increases in the cellular motility result in an
increase in the cells capacity of invasion [25].
Lumican is a keratin sulphate belonging to the SLRP
family of extracellular matrix (ECM) proteins and is
expressed in different forms in several tissues and or-
gans, such as cornea, bone, cartilage, artery, skin, kidney,
and lung. It has been found to have a key role both in the
organization of the extracellular matrix (ECM) and as an
important modulator of biological functions in breast,
lung, and pancreas cancer [26, 27], and it has been corre-
lated with lung cancer progression as well [28].
The peroxiredoxins were identified primarily by their
ability to protect the protein oxidative damage induced
by free radicals, such as reactive oxygen species (ROS)
and reactive nitrogen species (RNS), which is currently
recognizedas a promotor for cancer development [29].
The peroxirredoxins (Prdxs) are small proteins of sweep
(scavening) of H2O2, that could prevent tumor develop-
ment since the loss of Prdx1 in mice leads to premature
death due to cancer [30].
Keratins are expressed in all types of epithelial cells
(simple, stratified, keratinized and cornified), are import-
ant protectors of epithelial structural integrity under
Table 1 Differential expression of proteins in SCC/HPV-16 against control (without SIL and HPV infection)
Protein Expression index (n+/−) Accession number Chromosomal localization Gene Peptide coverage (%) Score
Mimecan 38.85 MIME_HUMAN 9q22 OGN 46 956
Mimecan 31.23 MIME_HUMAN 9q22 OGN 54 820
Actin, aortic smooth muscle 19.14 ACTA_HUMAN 10q23.31 ACTA2 59 311
Mimecan 17.77 MIME_HUMAN 9q22 OGN 54 447
Lumican 16.52 LUM_HUMAN 12q21.33 LUM 40 556
Peroxiredoxin-1 −8.37 PRDX1_HUMAN 1p34.1 PRDX1 79 968
14-3-3 protein sigma −14.97 1433S_HUMAN 1p36.11 SFN 67 977
Alpha-enolase −17.38 ENOA_HUMAN 1p36.2 ENO1 71 976
Keratin, type II cytoskeletal 5 −39.7 K2C5_HUMAN 12q13.13 KRT5 52 885
Keratin, type II cytoskeletal 5 −65.34 K2C5_HUMAN 12q13.13 KRT5 52 1 090
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conditions of stress, but have also been recognized as
regulators of other cellular functions, including motility,-
signaling, growth and protein synthesis [31]. KRT5
Keratin, type II cytoskeletal 5 was found decreased in
primary early-stage cervical squamous cell cancer tissue
with pelvic lymph node metastasis (PLNM) vs without
PLNM using DIGE-based proteomics [32].
Conclusion
Based on the above results, it was possible to identify
differential protein patterns among cases of cervical le-
sions related to cervical cancer progression with HPV-16
infection in comparison with tissue without lesion and
negative for HPV infection from Mexican women. These
proteins could be analyzed as potential candidates for
biomarkers due to their relationship with their presence
in early stages of cervical cancer development, improv-
ing the understanding of viral pathogenesis and its role
in the development of cervical cancer. Eventually this in-
formation could be used in the development of strategies
in clinical management, diagnosis and treatment.
Methods
Study population
A cross-sectional study was conducted, which included
two study groups, the first included a pool of 6 cases of
cervical cancer with HPV-16 infection (cervical cancer/
HPV-16) of which four cases were stage IIB, one stage
IB1 and one case stage IB2 and the second group, which
served as a comparison, consisted of a pool of four cases
from surgical specimens extracted by fibroids without le-
sions related to cervical cancer and without HPV infec-
tion, and whose previous cytological study showed
normal cells with reactive changes to nonspecific inflam-
matory processes, with normal colposcopy. All cases had
antecedents cytological that were reported according to
the Bethesda System 2001 and without coninfection by
Trichomonas vaginalis, Candida sp, Actinomyces sp and
Herpes simplex virus [33].
The diagnosis and detection of HPV in each sample
was performed as follows: three different sections of
each biopsy were obtained. The first embedded in paraf-
fin and were cut to a thickness of 3 μm (one stained
with hematoxylin-eosin for histopathological diagnosis,
another for detecting cell proliferation antigen Ki-67 and
finally another slide for detection of DNA detection
HPV by in situ hybridization with tyramide amplifica-
tion). The second section was used for detection of HPV
DNA by molecular analysis (INNOLiPA, Uniparts Inno-
genetics) and the third was used for protein extraction.
These data allowed the formation of the two compara-
tive groups (Table 2).
The cervical cancer tissues were obtained from the
Instituto Estatal de Cancerología “Arturo Beltrán
Ortega”, and normal cervix tissues from patients from
the Hospital General “Dr. Jorge Soberón Acevedo”.
The histopathological diagnosis was carried out by pa-
thologists in each institution independently, according
to each clinical record. Both groups contained women
with no history of prior local treatment, chronic de-
generative diseases, non-smoking and non-alcoholism
history, and without coinfections corroborated by
colposcopic, cytological and microbiological analyses.
The diagnosis was reported in accordance with the
system of the International Federation of Gynecology
and Obstetrics (FIGO) [34]. Ages in both groups were
37–69 years with a mean age of 50.7 years among cer-
vical cancer patients and 49.8 among patients free-
cervical. Women signed an informed consent and their
data were analyzed in a confidential manner. This
study was approved by the Committee of Bioethics at
the Autonomous University of Guerrero, Mexico, ac-
cording to the ethical guidelines of the Declaration of
Helsinki 2008 [35].
Table 2 Characteristics of cervical tissues samples of comparatives groups CC/HPV-16 and control without SIL and HPV infection
Testsa Pool CC/HPV-16 Pool without SIL and HPV infection (control)
Background Cytologicalb study: Squamous cell carcinoma
Colposcopic examination: cervical carcinoma
Clinical diagnosis: 4 cases stage IIB, one stage
IB1 and 1 case stage IB2
Cytologicalb study: normal cells with reactive
changes to nonspecific inflammatory processes
Normal colposcopy
Section 1 (paraffin embedding)
- Histopathological diagnosis (H-E)
- in situ hybridization with tyramide amplification
- Immunohistochemistry for Ki-67
Squamous Cell Carcinoma
Positive of HR- HPV
Positive in large pleomorphic nuclei of malignant




Positive in nuclei of parabasal cells in basal
layer
Section 2
- INNO-LIPA extra (Genotyping of HVP)
HPV-16 Negative of HPV infection
Section 3
- Extraction of proteins for 2D- DIGE and MALDI-TOF
Increased expression in cervical cancer Mimecan, Actin from aortic smooth muscle and Lumican.
Decreased expression: Keratin, type II cytoskeletal 5, Peroxiredoxin-1 and 14-3-3 protein sigma
aEach sample of tissue fragment into three sections and all tests were performed, six samples for group CC / HPV-16 and four samples were used for the control
group. For more details see section Methods
b Without coninfection by Trichomonas vaginalis, Candida sp, Actinomyces sp, Herpes simplex virus according to the Bethesda 2001 system
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Immunohistochemistry for Ki-67
To evaluate the expression of Ki-67, the monoclonal
antibody MIB-1 (Dako, Carpinteria, CA, USA) was used
with the Cytoscan HRP/DAB immunohistochemical sys-
tem of detection (Cell Marque Corporation, Hot Springs,
AR, USA [now relocated to Rocklin, CA, USA]). The
histological slices was deparaffinized and placed in a so-
lution of immunoDNA Retriever (BioSB, Inc., Santa Bar-
bara, CA, USA). Later, the primary antibody, previously
diluted in accordance with the manufacturer’s instruc-
tions, was added; the chromogen diaminobenzidine was
added; and finally, the specimens were stained with
Mayer’s hematoxylin (Merck, USA). The expression in
the without SIL tissues was evaluated in accordance to
the distribution and localization of the positive reaction
within the cells and within the depth of the epithelium.
The expression of Ki-67 was considered positive when a
brown ochre color was evident in the nucleus of the
cells. In SCC is observed in large pleomorphic nuclei of
malignant squamous cell form irregular nests invading
the stroma and tissue without SIL some cells of the
parabasal layers were found (Fig. 1).
Detection and genotyping of HPV DNA by in situ
hybridization with tyramide amplification and INNO-LiPA
Extra
In the in situ hybridization with a system of tyramide
signal amplification (Gen Point Dako Cytomation,
Carpinteria, CA, USA), a drop of test reagent (biotinyl-
ated viral DNA) with probes for 13 HR-HPV genotypes
(16,18,31,33,39,45,51,52,56,58,59 and 68) was added to
each slide. The slide were denatured for 10 min and
subjected to hybridization for 20 h (Hybridizer Dako,
Carpinteria, CA,USA). For HVP-INNO-LIPA extra,
the DNA extraction from cervical tissue samples the
conventional TRIZOL method (Cat. No.15596018,
Invitrogen a part of life Tech. Corp) was used, according
to the manufacturer’s instructions. Tissues were tested for
the presence of the HPV genotypes by polymerase chain
reaction (PCR), using the short PCR fragment 10 (SPF10)
primers, a highly sensitive method for HPV DNA detec-
tion, according to the method of Pirog et al. [36].
Protein sample labeling with CyDye
CyDye DIGE fluors (Cy2, Cy3, and Cy5) were used to
label the protein extracts following the manufacturer’s
protocol (GE Healthcare). The internal standard pool
was generated by combining equal amounts of extracts
from all samples, labeled with Cy2. Protein extracts from
the normal and cervical cancer cells were labeled with
Cy3 and Cy5, respectively. The labeling reaction was
performed on ice for 30 min in darkness, and was then
quenched with 10 mM lysine for 10 min on ice under
dark conditions. The labeled samples were then mixed
and prepared for the following steps.
2-D electrophoresis in polyacrylamide gel electrophoresis
(SDS-PAGE)
Total extracts from normal and cancer tissues were
processed according to Klose protocol [37]. Briefly, sam-
ples were diluted in rehydration buffer containing 8 M
urea, 0.5 % (w/v) CHAPS, 10 mM DTT, 0.001 % bromo-
phenol blue, and Bio-Lyte 3–10 Ampholyte (0.2 %) (Bio-
Rad, Cat. No.163-1113). The protein mixture was then
applied to ReadyStrip™ IPG 7 cm strips, pH 3–10 (lin-
ear). Rehydrated strips were isoelectrically focused using
a PROTEAN IEF cell System. To perform the second di-
mension analysis, the strips were processed by 10 %
SDS-PAGE. Finally the 2D gels were stained with Coo-
massie staining. The IPG strips were balanced in a buffer
consisting of 1.5 M Tris–HCl pH 8.8, 6 M urea and
30 % v/v glycerol, 2 % p/v SDS and traces of bromophe-
nol blue, being carried out in two steps, using in each
5 ml of balanced solution per strip; in the first one, the
strips were incubated in the balanced buffer described
above with 1 % w/v of DTT, remaining in this solution
for 20 min in agitation at room temperature. In the
second step, 2.5 % w/v of iodoacetamide was added
to the balanced buffer, repeating the 20 min incubation in
agitation at room temperature; once the procedure was
completed, the proteins could be picked for mass spec-
trometry analysis.
Image analysis
The images were analyzed using the DeCyder™ 2D
Differential Analysis Software (DeCyder 2D V8.0) by
differential in-gel analysis (DIA) and biological variation
analysis (BVA). Protein spots were marked and selected
with changes in abundance ratio >1.5-fold, P values <0.05
for protein identification. The gels were subjected to
Coomassie blue staining for spot visualization and
picking.
Protein identification by MALDI-TOF
Commassie-stained 2D gels were scanned and digital
images were compared using the Decyder Software. Each
pool was run three times. The electrophoretic entities of
interest were excised, alkylated, reduced, and digested
up to obtain a peptide mass fingerprint. Peak lists of the
tryptic peptide masses were generated using FlexAnaly-
sis1.2vSD1 Patch 2 (Bruker Daltonics). The search en-
gine MASCOT server 2.0 was used to compare the
fingerprints against human taxonomy with the following
parameters: one missed cleavage allowed, carbamido-
methyl cysteine as the fixed modification and oxidation
of methionine as the variable modification. Proteins with
scores greater than 50 and a p < 0.05 were accepted.
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